
## Giovanna Marrapese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11069101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 333-341.	2.4	26
2	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 256-262.e2.	2.3	56
3	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	3.7	95
4	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. Journal of Clinical Pathology, 2018, 71, 926-931.	2.0	12
5	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
6	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15
7	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778
8	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
9	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British Journal of Cancer, 2015, 113, 1730-1734.	6.4	65
10	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations Journal of Clinical Oncology, 2014, 32, 2502-2502.	1.6	18
11	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. Current Colorectal Cancer Reports, 2012, 8, 272-276.	0.5	1
12	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE, 2009, 4, e7287.	2.5	241
13	EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy. Oncology Reviews, 2009, 3, 187-193.	1.8	1
14	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology, The, 2005, 6, 279-286.	10.7	924

2